1 / 3

Hyperphosphatemia Drugs Market Opportunity Analysis, 2018 - 2026

Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, which leads to chronically high level of phosphate in blood.

RupeshD
Télécharger la présentation

Hyperphosphatemia Drugs Market Opportunity Analysis, 2018 - 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hyperphosphatemia Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026 Hyperphosphatemia Drugs Market, by Product Type (Calcium Carbonate, Calcium Acetate, Calcium Acetate/Magnesium Carbonate, Aluminum Hydroxide, Sevelamer Hydrochloride, Sevelamer Carbonate, Bixalomer, Lanthanum Carbonate, Sucroferric Oxyhydroxide, and Ferric Citrate), by Dosage Form (Tablet, Capsule, and Solution/Suspension), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026 Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, which leads to chronically high level of phosphate in blood. Hyperphosphatemia is very common in people with chronic kidney disease more often in people with end-stage kidney disease. Some other possible causes of hyperphosphatemia includes diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low parathyroid hormone levels. Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1315 For instance, in 2016, Astellas Pharma Inc. received marketing approval for its Kiklin Granules 86.2%, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission for new drug Fexeric (R) (ferric citrate coordination complex), indicated for the treatment of hyperphosphatemia in adults with chronic kidney disease. In 2014, Keryx Biopharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for drug Ferric Citrate (formerly known as Zerenex), a new, oral iron-based treatment for dialysis patients with

  2. hyperphosphatemia. In 2014, Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia (ferric citrate) tablets. Auryxia is an absorbable iron-based phosphate binder indicated for the treatment of hyperphosphatemia in chronic kidney disease Strategic merger and acquisition by key players in the market is also expected to create a lucrative environment for the hyperphosphatemia drugs market growth. For instance, in 2013, OPKO Health, Inc. acquired Canada-based Cytochroma Inc., with this strategic acquisition OPKO Health, Inc. has expanded its portfolio with Cytochroma Inc.’s Alpharen, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. Furthermore, Asia Pacific hyperphosphatemia drugs market is expected to witness significant growth in near future owing to increasing approval of novel hyperphosphatemia treatment drug in key regions such as China, and Japan. For instance, in 2014, Japan Tobacco Inc. and its subsidiary Torii Pharmaceutical Co., Ltd. received manufacturing and marketing approval of Riona Tablets 250 mg from Japanese Ministry of Health, Labor and Welfare. Riona tablet is indicated for treatment of hyperphosphatemia, it is a new phosphate binder containing ferric citrate hydrate as the active pharmaceutical ingredient. Browse More About the Keyword Market Study @ https://www.coherentmarketinsights.com/ongoing-insight/hyperphosphatemia-drugs-market- 1976 Report includes chapters which deeply display the following deliverable about industry: • Hyperphosphatemia Drugs Market Research Objective and Assumption • Hyperphosphatemia Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Hyperphosphatemia Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Hyperphosphatemia Drugs Market, By Regions • Hyperphosphatemia Drugs Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Hyperphosphatemia Drugs Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Hyperphosphatemia Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Hyperphosphatemia Drugs Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region.

  3. • Research Findings and Conclusion Table of Contents of Keyword Market Report: 1. Research Objective and assumption 2. Market Purview 3. Market Dynamics, Regulations, and Trends Analysis 4. Keyword Market, By Advanced Water Meters, 2017 - 2025 (USD Million) 5. Keyword Market, By Service, 2017 - 2025 (USD Million) 6. Keyword Market, By Solution, 2017 - 2025 (USD Million) 7. Keyword Market, By Regions, 2017 - 2025 (USD Million) 8. Competitive Landscape Ask for Discount before Buying @ https://www.coherentmarketinsights.com/insight/request-discount/1976 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related